Brainstorm Cell Therapeutics Inc. (BCLI) Could Burn Your Portfolio. The Stock Formed Multiple Bottom Pattern

June 12, 2018 - By Adrian Erickson

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

The stock of Brainstorm Cell Therapeutics Inc. (BCLI) shows a multiple bottoms pattern with $4.23 target or 8.00 % below today’s $4.60 share price. The 7 months chart pattern indicates high risk for the $87.91M company. It was reported on Jun, 12 by Finviz.com. If the $4.23 price target is reached, the company will be worth $7.03 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock decreased 0.43% or $0.02 during the last trading session, reaching $4.6. About 138,583 shares traded or 3.20% up from the average. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has risen 14.11% since June 12, 2017 and is uptrending. It has outperformed by 1.54% the S&P500.

Analysts await Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings on August, 13. They expect $-0.14 earnings per share, down 133.33 % or $0.08 from last year’s $-0.06 per share. After $-0.12 actual earnings per share reported by Brainstorm Cell Therapeutics Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Streetinsider.com which released: “Brainstorm Cell Therapeutics (BCLI) Releases Statement on ‘Right to Try’ Legislation” on May 25, 2018. Also Prnewswire.com published the news titled: “BrainStorm to Host Call Following President Trump’s Citing of Company’s ALS Treatment During “Right-to-Try” Bill …” on June 01, 2018. Seekingalpha.com‘s news article titled: “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q1 2018 Results – Earnings Call Transcript” with publication date: May 14, 2018 was also an interesting one.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $87.91 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: